ISSN:
0007-1048
eISSN:
1365-2141
Disciplines
(Field of Science):
- biomedical engineering (Engineering and Technology)
- medical biology (Medical and Health Sciences )
- pharmacology and pharmacy (Medical and Health Sciences )
- medical sciences (Medical and Health Sciences )
- health sciences (Medical and Health Sciences )
- biotechnology (Natural sciences)
(Field of Science)
Ministry points: Help
Year | Points | List |
---|---|---|
Year 2024 | 140 | Ministry scored journals list 2024 |
Year | Points | List |
---|---|---|
2024 | 140 | Ministry scored journals list 2024 |
2023 | 140 | Ministry Scored Journals List |
2022 | 140 | Ministry Scored Journals List 2019-2022 |
2021 | 140 | Ministry Scored Journals List 2019-2022 |
2020 | 140 | Ministry Scored Journals List 2019-2022 |
2019 | 140 | Ministry Scored Journals List 2019-2022 |
2018 | 40 | A |
2017 | 40 | A |
2016 | 40 | A |
2015 | 40 | A |
2014 | 40 | A |
2013 | 35 | A |
2012 | 35 | A |
2011 | 35 | A |
2010 | 32 | A |
Model:
Hybrid
Points CiteScore:
Year | Points |
---|---|
Year 2023 | 8.6 |
Year | Points |
---|---|
2023 | 8.6 |
2022 | 7.9 |
2021 | 7.4 |
2020 | 7.4 |
2019 | 8.1 |
2018 | 8.3 |
2017 | 7.9 |
2016 | 7.7 |
2015 | 7.1 |
2014 | 6.9 |
2013 | 7.7 |
2012 | 8.4 |
2011 | 8.1 |
Impact Factor:
Log in to see the Impact Factor.
Sherpa Romeo:
Papers published in journal
Filters
total: 3
Catalog Journals
Year 2018
-
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
Publication -
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy
Publication -
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
Publication
seen 423 times